gene 1,258 words KG: HNRNPA2B1 2026-03-24
kind:genesection:genesstate:published
Contents

HNRNPA2B1 - Heterogeneous Nuclear Ribonucleoprotein A2/B1

🧬 Gene Info
Gene SymbolHNRNPA2B1
Full NameHeterogeneous Nuclear Ribonucleoprotein A2/B1
AliasesPage for HNRNPA2B1
Chromosome7p15.2
Protein FamilyHnRNP A/B family
Protein TypeOther
Target ClassOther
FunctionTherapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated...
Mechanism of ActionTherapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated with neurodegeneration. These drugs could utilize antisense oligonucleotides to reduce HNRNPA2B1 expression or small molecules to inhibit its protein-protein interactions and RNA-binding functions.
DruggabilityLow (0.35)
Clinical StagePhase II
Molecular Weight36 kDa
Amino Acids341 aa
PathwaysRNA transport / hnRNP processing
UniProt IDP22626
NCBI Gene ID3181
Ensembl IDENSG00000122566
OMIM600124
GeneCardsHNRNPA2B1
Human Protein AtlasHNRNPA2B1
Associated DiseasesALS, Alzheimer's Disease, Amorphous Aggregates, Amyotrophic Lateral Sclerosis, Cancer
Known Drugs/CompoundsG-Quadruplex Structured Dna, Single-Stranded Dna, Ionic Strength, Irinotecan, Viral Genome G-Quadruplex
InteractionsIGF2BP1, CSNK2A1, NOTCH1, JUN, RANK, RANKL
SciDEX TargetView Target Profile (1 clinical trials)
SciDEX HypothesesAxonal RNA Transport Reconstitution
KG Connections421 knowledge graph edges
DatabasesGeneCardsHPASTRING

Knowledge Graph

Related Hypotheses (15)

Axonal RNA Transport Reconstitution
Score: 0.45
Phase-Separated Organelle Targeting
Score: 0.52
RNA Granule Nucleation Site Modulation
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Glycine-Rich Domain Competitive Inhibition
Score: 0.43

Related Analyses (4)

RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed

Related Experiments (8)

s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40

See Also (11)

CCNF Protein (Cyclin F)
protein · KG edge: expressed_in
Packard Center for ALS Research
institution · KG edge: associated_with
Dementia Australia
institution · KG edge: associated_with
Alzheimer Indonesia
institution · KG edge: activates
CSNK2A1 Gene
gene · KG edge: activates

Knowledge Graph (12 edges)

HNRNPA2B1 associated_with neurodegeneration
HNRNPA2B1 co_discussed NPM1
HNRNPA2B1 co_discussed SYNCRIP
HNRNPA2B1 co_discussed G3BP1
HNRNPA2B1 interacts_with IGF2BP1
HNRNPA2B1 associated_with HNRNPA1
HNRNPA2B1 associated_with VALOSIN
HNRNPA2B1 contributes_to HNRNPA1
HNRNPA2B1 activates CSNK2A1
HNRNPA2B1 activates NOTCH1